WEBULL
WebtradeDownload

Melisron (TASE:MLSR) Reports Mixed Earnings, Is The Stock Still Cheap?

Simply Wall St · 1d ago

Melisron (TASE:MLSR) drew fresh attention on 13 August 2026 after reporting second quarter and half year results, which showed higher sales alongside lower net income and earnings per share from continuing operations.

See our latest analysis for Melisron.

Melisron’s latest earnings update has come after a softer period for the stock, with the share price down about 5% year to date and around 6% over the past three months. However, the 1-year total shareholder return of 6.44% and 3-year total shareholder return of 84.04% still point to a much stronger longer term outcome, which hints that recent moves likely reflect a shift in sentiment around growth and risk rather than a complete break from the broader trend.

If this earnings story has you thinking about where else capital could work harder, it may be worth scanning 104 top founder-led companies as a way to surface other potentially compelling opportunities.

So is Melisron’s recent share price softness a sign that the weaker net income is biting into the investment case, or has sentiment simply cooled after strong multi year returns and left the stock trading off its underlying value?

Price-to-Earnings of 10.2x: Is it justified?

On a simple earnings basis, Melisron currently trades on a P/E of 10.2x, which looks lower than several reference points even after the recent share price softness to ₪405.

The P/E ratio compares the share price to earnings per share and is a quick way to see how much investors are paying for each unit of profit. For a commercial real estate company like Melisron, this often reflects how the market views the stability of rental income, the quality of assets and the consistency of earnings after any one off gains.

Here, the stock is described as good value on a P/E of 10.2x versus the wider Israel market on 15x. It is also described as good value compared with both the Israel real estate industry average of 12.9x and a peer group average of 12.8x. That points to a material discount in how current earnings are priced compared with similar companies.

With the P/E sitting below the broader market, the real estate industry and peer averages, the current earnings multiple suggests the stock trades at a marked discount to comparable profit streams rather than a premium.

Result: Price-to-Earnings of 10.2x (UNDERVALUED)

See what the numbers say about this price — find out in our valuation breakdown.

However, investors still need to watch for weaker rental conditions or a sharper pullback in real estate values that could challenge Melisron’s current earnings-based valuation.

Find out about the key risks to this Melisron narrative.

Another view on Melisron’s value

While Melisron screens as undervalued on a simple P/E of 10.2x, the SWS DCF model paints a very different picture. On that approach, the current price of ₪405 sits well above an estimated future cash flow value of ₪32.16. This points to a stock that screens as heavily overvalued on this measure.

This kind of gap can happen when reported earnings and accounting gains look strong, yet the longer term cash flow profile looks much lighter. It leaves investors with a simple question: Is the market correctly focusing on steady earnings, or is the DCF warning about future cash generation worth more weight?

Look into how the SWS DCF model arrives at its fair value.

MLSR Discounted Cash Flow as at Aug 2026
MLSR Discounted Cash Flow as at Aug 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Melisron for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 257 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of signals around Melisron leaves you undecided, it makes sense to move quickly and compare the data with your own expectations. To weigh both sides of the story in more detail, take a closer look at the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Melisron?

If Melisron has sharpened your focus on valuation and quality, now is a good time to widen the net and pressure test your ideas against other stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.